Mantle Cell Lymphoma Therapeutics Global Market Report 2024

The mantle cell lymphoma therapeutics market has grown strongly in recent years. It will grow from $2.26 billion in 2023 to $2.45 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The expansion observed in the historical period can be credited to progress in research, successful clinical trials, enhancements in diagnostic tools, the widening access to treatment, and collaborative research initiatives.

The mantle cell lymphoma therapeutics market is expected to see strong growth in the next few years. It will grow to $3.29 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be ascribed to advancements in targeted therapies, innovations in immunotherapy, trends in personalized medicine, the global expansion of the market, and the rising incidence rates. Key trends expected in the forecast period encompass advancements in immunotherapy, the development of precision medicine and biomarkers, targeted therapies addressing specific pathways, the utilization of combination therapies, and the integration of artificial intelligence (AI).

The anticipated increase in the prevalence of mantle cell lymphoma is set to drive the expansion of the mantle cell lymphoma therapeutics market. Mantle cell lymphoma (MCL) represents a form of non-Hodgkin lymphoma (NHL), impacting the lymphatic system. Therapeutics for mantle cell lymphoma play a pivotal role in curbing the prevalence of the disease by treating and managing the condition, leading to improved patient outcomes, prolonged survival, and diminished disease burden. As of December 2022, the National Library of Medicine, a US-based biomedical library operated by the United States Federal Government, reported an annual incidence of one case of mantle cell lymphoma per 200,000 people, contributing to 5% of all non-Hodgkin lymphomas. Thus, the escalating prevalence of mantle cell lymphoma is a catalyst for the growth of the mantle cell lymphoma therapeutics market.

The increasing availability of telemedicine services is poised to elevate the mantle cell lymphoma therapeutics market. Telemedicine services involve delivering healthcare services and medical consultations remotely, utilizing telecommunications technology. The surge in telemedicine services enhances accessibility, efficiency, and patient engagement within the mantle cell lymphoma therapeutics market, contributing to overall improved care and treatment outcomes. According to an October 2022 report from the Centers for Disease Control and Prevention, a US-based government agency, 37.0% of adults reported having utilized telemedicine services in the previous 12 months of 2021. Notably, women exhibited a higher likelihood of telemedicine usage (42.0%) compared to men (31.7%). Additionally, a positive correlation was observed between age and telemedicine usage, with the percentage of adults engaging in telemedicine rising from 29.4% among those aged 18-29 to 43.3% among adults aged 65 and above. Consequently, the growth of telemedicine services is propelling the mantle cell lymphoma therapeutics market.

A significant trend gaining traction in the mantle cell lymphoma therapeutics market is the development of targeted therapy drugs. Major players in the market are actively involved in creating new drugs for targeted therapy to maintain their market standing. For instance, in March 2023, AstraZeneca plc., a UK-based pharmaceutical company, received approval for Calquence (acalabrutinib) from the National Medical Products Administration (NMPA) to market the drug in China for adult patients with mantle cell lymphoma (MCL). Calquence (acalabrutinib) is a selective Bruton’s tyrosine kinase (BTK) inhibitor, offering a tolerable and effective new treatment option for controlling mantle cell lymphoma.

Companies operating in the mantle cell lymphoma therapeutics market are innovating by developing products such as kinase inhibitors to broaden their customer bases, increase sales, and boost revenue. A kinase inhibitor is a pharmaceutical agent that interferes with the activity of enzymes called kinases. In January 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced FDA approval for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), indicated for adult patients experiencing a recurrence or resistance to prior treatments for mantle cell lymphoma (MCL). Jaypirca, a highly selective kinase inhibitor, utilizes a unique binding mechanism and stands out for its ability to reestablish BTK inhibition in patients with mantle cell lymphoma who have undergone prior treatment with covalent BTK inhibitors.

In August 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired TeneoTwo Inc. for $1.3 billion. This strategic acquisition aims to diversify and strengthen AstraZeneca’s product portfolio by incorporating hematology and mantle cell lymphoma therapeutic drugs. TeneoTwo Inc., a US-based biotechnology company focusing on medicine development for oncology, operates in the mantle cell lymphoma therapeutics market.

Major companies operating in the mantle cell lymphoma therapeutics market report are AstraZeneca plc, Celgene Corporation, Johnson & Johnson Consumer Inc., Takeda Pharmaceutical Company Limited, Bayer Aktiengesellschaft, Eli Lilly and Company, Amgen Inc., GlaxoSmithKline plc, Kite Pharma Inc., Gilead Sciences Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Massive Bio Inc., Juno Therapeutics Inc., Nurix Therapeutics Inc., Janssen Biotech Inc., TG Therapeutics Inc., F. Hoffmann-La Roche AG, Astex Pharmaceuticals Inc., Astellas Pharma Inc., BeiGene Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Exelixis Inc., Hutchison China MediTech Limited, Incyte Corporation, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc.

North America was the largest region in the global mantle cell lymphoma therapeutics market in 2023. The regions covered in the mantle cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mantle cell lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of mantle cell lymphoma therapeutics encompass combination therapy and monotherapy. Combination therapy involves the simultaneous utilization of multiple treatments or medications to enhance their effectiveness in addressing a specific condition or disease. In the context of mantle cell lymphoma therapeutics, combination therapy integrates various approaches such as chemotherapy, targeted therapy, and immunotherapy to optimize treatment outcomes and enhance patient well-being. The drugs function through Bruton tyrosine kinase inhibitors, alkylating agents, deoxyribonucleic acid synthesis inhibitors, microtubule inhibitors, monoclonal antibodies, among others, and can be administered through oral and parenteral routes. These therapeutic interventions find application in hospitals, research institutes, and other healthcare settings.

The mantle cell lymphoma therapeutics market research report provides mantle cell lymphoma therapeutics market statistics, including the mantle cell lymphoma therapeutics industry global market size, regional shares, competitors with a mantle cell lymphoma therapeutics market share, detailed mantle cell lymphoma therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the mantle cell lymphoma therapeutics industry. This mantle cell lymphoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mantle cell lymphoma therapeutics market includes revenues earned by entities by brukinsa (zanubrutinib), imbruvica (ibrutinib), Revlimid (lenalidomide), and tecartus (brexucabtagene autoleucel). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.